Alteration of serum calcium and magnesium level in transfusion dependent thalassemic patients with combined iron chelator therapy

FatemaTuz Munira1, Shelina Begum2, S.F.H Urmi1
1. Department of Physiology, Armed Forces Medical College, Dhaka.
2. Department of Physiology, Bangabandhu Sheikh Mujib Medical University, Dhaka.

Abstract

Background: Regular blood transfusion and iron chelation is the primary treatment of thalassemia patients to maintain their life. Iron chelators may alter serum total calcium and magnesium level in TDT patients. Objective: To evaluate any alteration of serum total calcium and magnesium level in transfusion dependent thalassemia patients treated with iron chelator. Method: The present cross sectional study was carried out in the department of Physiology, BSMMU, Dhaka between September 2017 to February 2019. Thirty cases of TDT, aged 5-40 year were included in the study group. Age and sex matched 30 healthy subjects were also studied as control. All the TDT patients were selected from the outpatient Department of Hematology and Transfusion Medicine, BSMMU, Dhaka. Serum total calcium, magnesium and ferritin levels were measured by colorimetric method. For statistical analysis independent sample t test and Chi-Square test and Pearson correlation coefficient test were used. Result: The mean serum total calcium and magnesium levels were significantly (p<0.05) lower and serum ferritin level was significantly (p<0.001) higher in study group compared to that of control. Again, in this study group 6.7 % TDT patients had hypocalcemia and 13.3% TDT patients had hypomagnecemia. Conclusion: This study may conclude that low serum total calcium and magnesium level may be associated with TDT patients treated by combined deferoxamine (DFO) & deferiprone (DFP) iron chelator.

Key words: TDT, total calcium, magnesium, iron chelators (DFP and DFO).
Alteration of serum calcium and magnesium level in transfusion dependent thalassemia

Munira et al

Introduction

Thalassemia is a group of autosomal recessive hereditary blood disorder in which there are defective synthesis of alpha or beta globin subunit of hemoglobin. About 150 million people carry the thalassemia gene worldwide but it is most common in Mediterranean regions, Middle East, part of Africa, Central Asia, India sub-continent, Southern China and into the Pacific island. According to World Health Organization about 3% population are carrier of beta thalassemia and about 4% population are carrier of Hb-E in Bangladesh. The principal treatment of thalassemia involve blood transfusion to correct anemia. The repeated blood transfusion may lead to accumulation of excess iron in the body causing oxidative stress and organ damage. The most common cause of death is heart failure due to transfusional iron overload. So, several iron chelators have been used to remove the excess iron from the body. Currently there are three approved commercially available iron chelators – deferoxamine (DFO), deferiprone (DFP), deferasirox (DFX).

Ferritin binds with iron and stores excess iron within the cell and iron overload causes high concentration of serum ferritin. Therefore, estimation of serum ferritin is the most commonly used, easy and in-expensive test to evaluate iron overload in patients with thalassemia.

Calcium is the main component of the body. More than 99% is stored in the bones and teeth. Less than 1% is found in extracellular fluid. Calcium is required for vascular contraction and vasodilation, muscle function, nerve transmission, intracellular signaling and hormonal secretion. Calcium deficiency causes fatigue, neuromuscular instability, numbness and tingling sensation of extremity, muscle cramp, chest pain, irritability.

Magnesium play an essential role in the activity of many enzymes involved cellular metabolism. It act as a modulator in cell volume regulation, immune system, cardiovascular system and musculoskeletal system. Deficiency of magnesium causes fatigue, muscle cramp, irregular heart beat, neuromuscular instability, hypertension, diabetes. Data on these minerals in TDT patients treated with iron chelator is vary few. Therefore, this study has been designed to evaluate calcium, magnesium and ferritin levels in TDT patients with iron chelator. Data on these minerals in TDT patients treated with iron chelator is very few. Therefore, this study has been designed to evaluate any alteration of serum total calcium and magnesium levels in TDT patients treated with iron chelator.

Methods

The present cross sectional study was carried out in the department of Physiology, BSMMU, Dhaka between September 2017 to February 2019 and protocol of this study was approved by Institutional Review Board, BSMMU, Shahbag, Dhaka. Serum total calcium, magnesium, ferritin and Hb levels on 30 TDT patients treated with combined iron chelator (DFP) and (DFO) and 30 healthy subjects (control), age ranged from 5-40 year were assessed. TDT patients were selected from outpatient Department of Hematology and Transfusion Medicine, BSMMU and control were selected among the relatives and attendants of patients, hospital staff and subjects available in the BSMMU campus and also personal contact. Subjects with history of renal disease, any acute and chronic disease, vitamin and minerals supplementation were excluded from...
Alteration of serum calcium and magnesium level in transfusion dependent

the study. After selection of the subjects, the purpose of the study was explained to each subjects and informed written consent was taken. Detailed family and medical history, Anthropometric measurement were recorded. For estimation of serum total calcium, magnesium, ferritin and Hb levels 5 ml of venous blood was collected from ante-cubital vein under aseptic precaution from each subject and serum was prepared for these biochemical tests.Serum total calcium, magnesium and ferritin was measured by colorimetric method. Data were expressed as Mean±SE. Data analysis was done with SPSS version 16. For statistical analysis independent sample t test and Chi-Square test and Pearson correlation coefficient test were performed.

Results
In this study, all the groups were matched for age and sex but BMI (p<0.05) and Hb (p<0.001) were significantly lower in TDT compared to that of control (Table I). Mean serum total calcium and magnesium levels were significantly (p<0.001) lower and mean serum ferritin was significantly (p<0.001) higher in TDT patients compared to that of control (Table II).

Table I: Age, BMI and Hb in both groups (N=60)

| Parameter      | Control (n=30) | TDT (n=30) |
|----------------|----------------|------------|
| Age (years)    | 19.86±1.57     | 19.66±1.68 |
| Male no(%)     | 15(50%)        | 15(50%)    |
| Female no(%)   | 15(50%)        | 15(50%)    |
| BMI (Kg/m²)    | 21.87±0.89     | 18.54±0.56*|
| Hb (g/dl)      | 13.75±0.19     | 7.78±0.36***|

Data are expressed as Mean±SE. Statistical analysis was done by independent sample t test and Chi-Square test. BMI-Body mass index; Hb-Hemoglobin; TDT-Transfusion dependent thalassemia. "p<0.05, ***p<0.001.

Again, in this study 6.7% TDT patients had hypocalcemia and 13.3% TDT patients had hypomagnecemia. No control had hypocalcemia or hypomagnecemia (Table III).

Table II: Serum total calcium, magnesium and ferritin levels in both groups (N=60)

| Parameter      | Control (n=30) | TDT (n=30) |
|----------------|----------------|------------|
| Serum total calcium | 9.1±0.08      | 8.62±0.14***|
| Serum magnesium | 1.91±0.02      | 1.76±0.03***|
| Serum ferritin  | 40.39±7.68     | 6276.85±709.82***|

Data are expressed as Mean±SE. Statistical analysis was done by independent sample t test. TDT-Transfusion dependent thalassemia; ***p<0.001. Cut point for total calcium-8.1mg/dl, cut point for magnesium-1.6 mg/dl.

In addition serum total calcium level was positively correlated and serum magnesium level was negatively correlated with serum ferritin level in study group (Figure 1,2). Moreover, serum serum total calcium and magnesium both were negatively correlated with duration of iron chelation therapy (Figure 3,4). All these correlations were statistically non-significant.
Alteration of serum calcium and magnesium level in transfusion dependent

Discussions

The present study observed any alteration of serum total calcium and magnesium levels in TDT patients treated with combined iron chelator.

The result of this study showed significantly lower serum total calcium and magnesium level in all TDT patients treated with combined (DFP+DFO) iron chelator than control. On the other hand, Salva found significantly lower and Either et al. found non-significantly lower serum calcium level in TDT patient treated with DFP and DFO iron chelator separately.\(^{16-17}\) Again, Genc et al. found significantly lower serum
magnesium level in TDT patient treated with only DFO iron chelator. Moreover significant number of TDT patients in this study were suffering from calcium and magnesium deficiency.

In this study, non-significant positive correlation of serum calcium and negative correlation of serum magnesium with serum ferritin level was observed. Genc et al. also found negative correlation of serum magnesium with serum ferritin in TDT patient with DFP iron chelator. In addition, serum total calcium and magnesium levels were negatively correlated with duration of iron chelation therapy.

The presence of calcium and magnesium deficiency in the TDT patients under combined chelator therapy cannot be explained from this study. Various literatures suggested that binding of iron chelator with metal depend on stability constant of metal ion, relative concentration of metal cation in blood and heterocyclic ring formation. In our body fluid calcium is readily available that is why calcium may first bind with chelator than other higher stability constant of metal such as iron and lead. Magnesium may form more number of heterocyclic ring with iron chelator. For this iron chelator may remove magnesium from the body along with iron.

Moreover, minerals alteration in TDT patients may be due to oxidative stress, excessive hemolysis, dietary deficiency, psychological problems (such as depression), metabolic and endocrine complications. 

Conclusion

After analyzing the result of the study, it can be concluded that low serum calcium and magnesium level may occur in TDT patients treated with combined (DFP + DFO) iron chelator. So, estimation of serum total calcium and magnesium level may be helpful for proper management of TDT patients.

Conflict of interest

None.

Acknowledgement

The authors acknowledge the Department of Hematology and Transfusion Medicine, BSMMU, Dhaka for their kind co-operation during sample collection and Armed Forces Institute of Pathology, Dhaka cantonment regarding laboratory tests.

References

1. Sultan S, Irfan SM, Kaker J, Zeeshan R. Effect of iron chelator desferrioxamine on serum zinc levels in patients with beta thalassemia major. Malays J Pathol 2015; 37(1):35-8.
2. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood J 2011;118(13): 3479-88.
3. Galanello R, Origa R. Beta thalassemia. Orphanet J Rare Dis 2010;5(11):1-15.
4. Mahyar A, Ayazi P, Pahlean A, Mojabi H, Sehhat R, Javadi A. Zinc and copper status in children with beta-thalassemia major. Iran J Pediatr 2010;20(3): 297-302.
5. Amin SK. Prevention of thalassemia by genetic counseling. Anwer Khan Mod Med Coll J 2011;2(2):26-8.
6. Tahura S, Selimuzzaman M, Khan W. Thalassemia prevention : Bangladesh perspective - A current update. Bangladesh J Child Health 2016;40(1):31-8.
7. Baski AJ, Pennell DJ. Randomized controlled trails of iron chelators for the treatment of cardiac siderosis in thalassemia major. FrontiersPharmacol 2014;5: 217-22.
8. Genc GE, Ozturk Z, Gumuslu S, Kupesiz A. Minerals level in thalassemia major patients using different ironchelators. Biol Trace Elem Res 2016;170:9-16.
9. Kannengiesser C, Jouanolle M, Hetet G, Mosser A, Muzeau F, Henry D et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 2009;34(3):335-39.
10. Ikram N, Hassan K, Younas M, Amanat S. Ferritin levels in patients of beta thalassemia major. Int J Pathol 2004;2(2):71-4.
11. Shazia Q, Mohammad ZH, Rahman T, Shekhar U. Correlation of oxidative stress with serum trace element level and antioxidant enzyme status in beta thalassemia major patient: A review of the literature. Anemia 2012;1:1-7.
12. Jeon US. Kidney and calcium homeostatis. Postech Biotech Center 2008; 6: 68-76.
13. Rowe AJM. The thalassemias and related disorders. Bayl Univ Med Cent 2007; 20(1): 27-31.
14. Beto JA. The role of calcium in human aging. Clin Nutr Res 2015; 4:1-8.
15. Goyal M, Abrol P, Lal H. Parathyroid and calcium status in patients with thalassemia. Indian j Clin Biochem 2010; 25(4): 385-87.
16. Salva S. Assessment of serum calcium and phosphorus levels among transfusion-dependent beta thalassemia major patients on chelation therapy. J postgard Med Inst 2014; 29(30):168-71.
17. Eithar EK, Salam KM, Nagwa E. An update study of some trace element in patients with thalassemia major. World J Med Sci 2013;9(2):97-101.
18. Flora S.J.S, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health 2010; 7 (7): 2745-88.
19. Widad NM, Al-Naama LM, Hassan MK. Trace elements in patients with beta thalassemia major. Haema2003; 6(3): 376-83.
20. Al-Samarrai AH, Adaay MH, Al-Tikriti KA. Evaluation of some essential element level in thalassemia major patients in Mousaldistic, Iraq. Saudi Med J [Internet]. 2008 Nov[cited 2018 April 10];29(1):94-7. Available from::https://www.ncbi.nlm.nih.gov/pubmed/18176681
21. Ali AM, Handoka NM, El Kalioby MI. Serum zinc level in beta thalassemia major children receiving iron chelators. Egyp J of Paediat [Internet]. 2014 Jan [cited 2018 April 4];31(1-2):87-101. Available from::https://link.springer.com/content/pdf/10.1007%2Fs12011-017-1158-0.pdf